ÄÉÆæÅØÇöó½ºÅ¸(ÄÉÅäÇÁ·ÎÆæ) KEFENTEC PLASTA[Ketoprofen]
ÀϹÝÀǾàǰ | »èÁ¦
¾Ë¸²:
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù.
Àü¹®/ÀϹÝ
ÀϹÝ
ÀÌ ¾àÀº ¹«»öÅõ¸íÀÇ Á¡Âø¼º ¹°ÁúÀ» ¸°Æ®Æ÷¿¡ µµÆ÷ÇÏ°í °íü¸é¿¡ ¹Ú¸®Áö¸¦ µ¤Àº °æ°íÁ¦ÀÌ´Ù
Á¦Á¶È¸»ç
Á¦ÀϾàǰ(ÁÖ)
ÆÇ¸Åȸ»ç
Á¦ÀϾàǰ(ÁÖ)
Çã°¡Á¤º¸
Á¤»ó
(1996.04.19)
BIT ¾àÈ¿ºÐ·ù
¿Ü¿ë ¼Ò¿°ÁøÅëÁ¦ (NSAIDs : Skin & Mucous Membrane)
º¹ÁöºÎºÐ·ù
264[ÁøÅ롤Áø¾ç¡¤¼ö·Å¡¤¼Ò¿°Á¦ ]
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå
645401830[A04203691] \0 ¿ø/1¸Å(2017.08.01) (ÇöÀç¾à°¡) \126 ¿ø/1¸Å(2016.01.01) (º¯°æÀü¾à°¡)
ATCÄÚµå
Ketoprofen / M02AA10
NDCÄÚµå
[Proprietary Name Search _ ƯÇãµî·Ï¸í,»óÇ¥¸íÀ¸·Î °Ë»ö]
[Active Ingredient Search _ ÁÖ¼ººÐÀ¸·Î °Ë»ö]
[NDC Number Search _ NDCÄÚµå·Î °Ë»ö]
¼ººÐ / ÇÔ·®
[½ÉÆò¿ø ÁÖ¼ººÐÄÚµå ±âÁØ ¼ººÐÇÔ·®Á¤º¸ Á¶È¸]
÷°¡Á¦
±Û¸®¼¼¸° ,
¸°Æ®Æ÷ ,
¹Ì³×¶öÀ¯ ,
¹Ì³×¶öÀ¯ ,
¹Ù´ÒºÎÆ¿¿¡Å׸£ ,
¹Ú¸®Áö ,
¹ÚÇÏÀ¯ ,
¾Ëų¾ÆÅ©¸±·¹ÀÌÆ®/ºñ´Ò¾Æ¼¼Å×ÀÌÆ® °øÁßÇÕü¿ë¾× ,
¾Ëų¾ÆÅ©¸±·¹ÀÌÆ®/ºñ´Ò¾Æ¼¼Å×ÀÌÆ® °øÁßÇÕü¿ë¾×(°íÇü ,
¾Ëų¾ÆÅ©¸±·¹ÀÌÆ®/ºñ´Ò¾Æ¼¼Å×ÀÌÆ® °øÁßÇÕü¿ë¾×(°íÇüºÐ 48%) ,
À̼ÒÇÁ·ÎÇʹ̸®½ºÅ×ÀÌÆ® ,
ÅäÄÚÆä·Ñ¾Æ¼¼Å×ÀÌÆ® ,
l-¸àÅç
À¯·áȸ¿ø °áÀç½Ã ¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸ ¸¦
ÀÌ¿ë ÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·Ï Àº Àü¹®È¸¿ø À¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
Çã°¡Á¤º¸
Ç׸ñ
³»¿ë
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇѱݾ×
645401830[A04203691]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1¸Å(2017.08.01) (ÇöÀç¾à°¡)
\126 ¿ø/1¸Å(2016.01.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
[¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]
ºü¸¥Á¶È¸
Á¦Ç°¼º»ó
ÀÌ ¾àÀº ¹«»öÅõ¸íÀÇ Á¡Âø¼º ¹°ÁúÀ» ¸°Æ®Æ÷¿¡ µµÆ÷ÇÏ°í °íü¸é¿¡ ¹Ú¸®Áö¸¦ µ¤Àº °æ°íÁ¦ÀÌ´Ù
[Á¦ÇüÁ¤º¸ È®ÀÎ]
Æ÷À塤À¯Åë´ÜÀ§
30mg/70§²¡¿70§²/¸Å¡¿7EA, 6EA, 40EA, 10EA
Æ÷À塤ÄÚµå´ÜÀ§
¾àǰ±Ô°Ý
´ÜÀ§
´ëÇ¥ÄÚµå
Ç¥ÁØÄÚµå
ºñ°í
30¹Ð¸®±×·¥
5 ¸Å
8806454018309
8806454018446
10cm X 7cm
30¹Ð¸®±×·¥
20 ¸Å
8806454018309
8806454018439
10cm X 7cm
30¹Ð¸®±×·¥
600 ¸Å
8806454018309
8806454018422
10cm X 7cm
30¹Ð¸®±×·¥
300 ¸Å
8806454018309
8806454018415
10cm X 7cm
30¹Ð¸®±×·¥
120 ¸Å
8806454018309
8806454018392
10cm X 7cm
30¹Ð¸®±×·¥
40 ¸Å
8806454018309
8806454018385
10cm X 7cm
30¹Ð¸®±×·¥
30 ¸Å
8806454018309
8806454018378
10cm X 7cm
30¹Ð¸®±×·¥
10 ¸Å
8806454018309
8806454018361
10cm X 7cm
30¹Ð¸®±×·¥
7 ¸Å
8806454018309
8806454018354
10cm X 7cm
30¹Ð¸®±×·¥
6 ¸Å
8806454018309
8806454018347
10cm X 7cm
30¹Ð¸®±×·¥
3 ¸Å
8806454018309
8806454018330
10cm X 7cm
30¹Ð¸®±×·¥
2 ¸Å
8806454018309
8806454018323
10cm X 7cm
30¹Ð¸®±×·¥
1 ¸Å
8806454018309
8806454018316
10cm X 7cm
30¹Ð¸®±×·¥
34 ¸Å
8806454018309
8806454018484
30¹Ð¸®±×·¥
4 ¸Å
8806454018309
8806454018477
10cmX7cm
30¹Ð¸®±×·¥
8 ¸Å
8806454018309
8806454018460
10cmX7cm
30¹Ð¸®±×·¥
7 ¸Å
8806454018309
8806454018453
10cmX7cm
ÁÖ¼ººÐÄÚµå
179901CPL
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
´ëÇ¥ÄÚµå
8806454018309
º¸°ü¹æ¹ý
Â÷±¤ÇÑ ±â¹Ð¿ë±â, ½Ç¿Âº¸°ü
¾à¸®ÀÛ¿ë
[Á¶È¸]
È¿´ÉÈ¿°ú
[ÀûÀÀÁõ º° °Ë»ö]
´ÙÀ½ Áúȯ ¹× Áõ»óÀÇ ÁøÅë ․ ¼Ò¿°[Ç׿°] : ÅðÇ༺°üÀý¿°(°ñ°üÀý¿°), ¾î±ú°üÀýÁÖÀ§¿°, °Ç[ÈûÁÙ] ․ °ÇÃÊ¿°[ÈûÁÙÀ±È°¸·¿°], °Ç[ÈûÁÙ]ÁÖÀ§¿°, »ó¿Ï°ñ[À§ÆÈ»À]»ó°ú¿°(Å״Ͻº ¿¤º¸¿ì µî), ±ÙÀ°Åë, ¿Ü»ó[»óó]ÈÄÀÇ Á¾Ã¢[ºÎ±â] ․ µ¿Åë[ÅëÁõ]
¿ë¹ý¿ë·®
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¾à¸éÀÇ ¹Ú¸®[¹þ°ÜÁü]Áö¸¦ ¶¼¾î³½ ÈÄ È¯ºÎ[Áúȯ ºÎÀ§]¿¡ 1ÀÏ 2ȸ ºÎÂøÇÕ´Ï´Ù.
±Ý±â
1) ÀÌ ¾à ¹× ÀÌ ¾à ¼ººÐ¿¡ °ú¹ÎÁõ ¹× ±¤°ú¹ÎÁõÀÇ º´·ÂÀÌ Àִ ȯÀÚ
2) ¾Æ½ºÇǸ° õ½Ä(ºñ½ºÅ×·ÎÀ̵强 ¼Ò¿°(Ç׿°)ÁøÅëÁ¦ µî¿¡ ÀÇÇÑ Ãµ½Ä¹ßÀÛÀÇ À¯¹ß) ¶Ç´Â ±× º´·ÂÀÌ Àִ ȯÀÚ(õ½Ä¹ßÀÛÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Ù)
3) ´ÙÀ½ÀÇ ¾à¹°¿¡ °ú¹ÎÁõÀÇ º´·ÂÀÌ Àִ ȯÀÚ : Ƽ¾ÆÇÁ·ÎÆæ»ê, Æä³ëÇǺ극ÀÌÆ®, º£ÀÚÇǺ극ÀÌÆ®, ½ÃÇÁ·ÎÇǺ극ÀÌÆ®, ¿Á½Ãº¥Á¸(ÄÉÅäÇÁ·ÎÆæ°ú ±³Â÷°ú¹Î¹ÝÀÀÀ» À¯¹ßÇÒ ¼ö ÀÖ´Ù)
4) ÀӽűⰣ 6°³¿ù ÀÌ»óÀÎ ÀӺΠ: ÀӽŸ»±âÀÇ ·§Æ®¿¡ ÀÌ ¾àÀ» °æ±¸Åõ¿©ÇÑ(º¹¿ëÇÑ) ½ÇÇè¿¡¼ ÅÂÀÚÀÇ µ¿¸ÆÇ÷°ü¼öÃàÀÌ º¸°íµÇ¾ú´Ù. ÀÓ½ÅÈı⿡ Åõ¿©(°æ±¸, ÁÖ»ç, Á÷Àå(°ðâÀÚ, Á÷Àå)ÁÖÀÔ)½Ã Áö¼Ó¼º žƼøÈ¯, ÅÂ¾Æ ½ÅºÎÀüÀÌ ³ªÅ¸³µ´Ù´Â º¸°í°¡ ÀÖ´Ù.
5) 15¼¼ ¹Ì¸¸ÀÇ ¼Ò¾Æ
½ÅÁßÅõ¿©
1) ±â°üÁö õ½Ä ȯÀÚ(õ½Ä¹ßÀÛÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Ù)
2) ÀÇ»çÀÇ Ä¡·á¸¦ ¹Þ°í Àִ ȯÀÚ
3) ÀӺΠ¶Ç´Â ¼öÀ¯ºÎ (¾ÈÀü¼ºÀÌ È®¸³µÇ¾î ÀÖÁö ¾ÊÀ¸¹Ç·Î ´ë·® ¶Ç´Â ±¤¹üÀ§¿¡ °ÉÄ£ Àå±â°£ÀÇ »ç¿ëÀº ÇÇÇÑ´Ù.)
ÀÌ»ó¹ÝÀÀ
1) µå¹°°Ô ¼ï, ¾Æ³ªÇʶô½Ã¾ç Áõ»ó(µÎµå·¯±â, È£Èí°ï¶õ, ¾ó±¼ºÎ±â µî °ú¹Î¼ºÀ¯»çÁõ»ó)ÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â »ç¿ëÀ» ÁßÁöÇÑ´Ù.
2) õ½Ä¹ßÀÛÀ» À¯¹ßÇÒ ¼ö ÀÖÀ¸¹Ç·Î °Ç¼º ¼öÆ÷À½(°Åǰ¼Ò¸®), õ¸í(¼ûÀ» ½Ù½Ù°Å¸²), È£Èí°ï¶õ µîÀÇ ÃʱâÁõ»óÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â »ç¿ëÀ» ÁßÁöÇÑ´Ù. õ½Ä¹ßÀÛÀº ÀÌ ¾à Àû¿ë ÈÄ ¼ö½Ã°£ ³»¿¡ ³ªÅ¸³´Ù.
3) ÇǺΠ: ¶§¶§·Î ¹ßÀû, ¹ßÁø, °¡·Á¿ò, ¼öÆ÷, Áþ¹«¸§, Àڱذ¨ ¹× Á¾Ã¢(ºÎ±â) µîÀÇ Á¢ÃËÇǺο°, ÇǺΰÇÁ¶ ¹× »ö¼ÒÄ§ÂøÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. ¶ÇÇÑ Á÷»çÀϱ¤(Àڿܼ±)¿¡ ÀÇÇØ ±¤°ú¹ÎÁõÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç ÇǺιßÁøÀÌ Àü½ÅÀ¸·Î È®´ëµÉ ¼ö ÀÖ´Ù. ÀÌ·¯ÇÑ Áõ»óÀÌ ½ÉÇÑ °æ¿ì¿¡´Â »ç¿ëÀ» ÁßÁöÇÑ´Ù.
4) 1ÁÖÀÏ Á¤µµ »ç¿ëÇÏ°íµµ Áõ»ó°³¼±ÀÌ º¸ÀÌÁö ¾ÊÀ» °æ¿ì »ç¿ëÀ» ÁßÁöÇϰí ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »óÀÇÇÑ´Ù.
ÀϹÝÀû ÁÖÀÇ
1) ÀÌ ¾àÀ» »ç¿ë ÁßÀ̰ųª »ç¿ë ÈÄ 2ÁÖ±îÁö´Â ³¯¾¾¿¡ °ü°è¾øÀÌ, ¿Á¿ÜȰµ¿À» ÇÇÇϰí, ÀÏ»ó ¿ÜÃâÇÒ ¶§¿¡´Â ÀÌ ¾àÀÇ µµÆ÷(¹Ù¸¥)ºÎÀ§¸¦ ¿Ê, ¼±±Û¶ó½º, ¸ðÀÚ, Àڿܼ± Â÷´ÜÁ¦ µîÀ¸·Î °¡·Á Àڿܼ±¿¡ ³ëÃâµÇÁö ¾Êµµ·Ï ÇÑ´Ù. Èò»öÀ̳ª ¾ãÀº ¿ÊÀº Àڿܼ±À» Åõ°ú½Ãų ¼ö ÀÖÀ¸¹Ç·Î À¯»ö ¿ÊÀ» ÀԴ´Ù.(Àڿܼ±¿¡ ÀÇÇØ, »ç¿ë Áß ¶Ç´Â »ç¿ë ÈÄ ±¤°ú¹ÎÁõÀÌ ³ªÅ¸³µ´Ù´Â º¸°í°¡ ÀÖ´Ù.)
2) ÀÌ ¾à¿¡ ÀÇÇÑ Ä¡·á´Â ¿øÀοä¹ýÀÌ ¾Æ´Ñ ´ëÁõ¿ä¹ý(Áõ»óº°·Î Ä¡·áÇÏ´Â ¹æ¹ý)ÀÌ´Ù.
3) ÇǺΰ¨¿°ÁõÀ» µå·¯³ªÁö ¾Ê°Ô ÇÒ ¼ö ÀÖÀ¸¹Ç·Î °¨¿°¿¡ ¼ö¹ÝµÇ´Â ¿°Áõ¿¡ »ç¿ëÇÏ´Â °æ¿ì¿¡´Â ÀûÀýÇÑ Ç×±ÕÁ¦ ¶Ç´Â Ç×Áø±ÕÁ¦¸¦ º´¿ë[ÇÔ²² º¹¿ë(»ç¿ë)]Çϰí ÃæºÐÈ÷ °üÂûÇÏ¿© ºÎÀÛ¿ë ¹ßÇö(µå·¯³¿)¿¡ À¯ÀÇÇÑ´Ù.
4) ¸¸¼ºÁúȯ(ÅðÇ༺°üÀý¿°(°ñ(»À)°üÀý¿°) µî)¿¡ »ç¿ëÇÏ´Â °æ¿ì¿¡´Â ¾à¹°¿ä¹ý ÀÌ¿ÜÀÇ ¿ä¹ýµµ °í·ÁÇÑ´Ù. ¶ÇÇÑ »óŸ¦ ÃæºÐÈ÷ °üÂûÇÏ¿© ÀÌ»ó¹ÝÀÀ¿¡ À¯ÀÇÇÑ´Ù.
5) ´« ¹× Á¡¸·¿¡´Â »ç¿ëÇÏÁö ¾Ê´Â´Ù.
6) ¼Õ»óµÈ ÇǺΠ¹× Á¡¸·, ½ÀÁø ¶Ç´Â ¹ßÁø ºÎÀ§¿¡ »ç¿ëÇÏ´Â °æ¿ì ÀϽÃÀûÀÎ ÀÚ±Ø ¹× ³¯Ä«·Î¿î ÅëÁõÀ» ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¹Ç·Î »ç¿ë½Ã ÁÖÀÇÇÑ´Ù
7) ¹«Á», ¹é¼± µî¿¡´Â »ç¿ëÇÏÁö ¾Ê´Â´Ù.
8) ¹ÐºÀºØ´ë¹ýÀ» »ç¿ëÇÏÁö ¾Ê´Â´Ù.
º¸°ü ¹× Ãë±Þ»óÀÇ ÁÖÀÇ
1) ¾î¸°ÀÌÀÇ ¼ÕÀÌ ´êÁö ¾Ê´Â °÷¿¡ º¸°üÇϽʽÿÀ.
Related FDA Approved Drug
Á¤º¸¿ä¾à
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
ÄÚµå ¹× ºÐ·ùÁ¤º¸
Ç׸ñ
³»¿ë
¼ººÐÄÚµå
M051464/ÄÉÅäÇÁ·ÎÆæ 30.0¹Ð¸®±×·¥ /
ÁÖ¼ººÐÄÚµå
179901CPL
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
´ëÇ¥ÄÚµå
8806454018309
BIT ¾àÈ¿ºÐ·ù
¿Ü¿ë ¼Ò¿°ÁøÅëÁ¦ (NSAIDs : Skin & Mucous Membrane)
ATC ÄÚµå
Ketoprofen / M02AA10
[ÄÚµåºÐ·ù»ó¼¼¼³¸í]
[ATCÄÚµå¿¹Ãø]
º¹ÁöºÎºÐ·ùÄÚµå
264 (ÁøÅ롤Áø¾ç¡¤¼ö·Å¡¤¼Ò¿°Á¦ )
ÀǾàǰ ¹ÙÄÚµåÁ¤º¸
³»¿ëº¸±â
ÄÉÆæÅØÇöó½ºÅ¸(ÄÉÅäÇÁ·ÎÆæ)(¼öÃâ¸í:KEFEN) /
A04203691
Á¦Ç°±Ô°Ý:
/Á¦Ç°¼ö·®:
1 /Á¦Çü:
¸Å
Æû¸ñ±âÁØÄÚµå:
199600561 /´ëÇ¥ÄÚµå:
8806454018309 /Ç¥ÁØÄÚµå:
8806454018316
±¸¹ÙÄÚµå:
- /ºñ°í:-
ÄÉÆæÅØÇöó½ºÅ¸(ÄÉÅäÇÁ·ÎÆæ)(¼öÃâ¸í:KEFEN) /
A04203691
Á¦Ç°±Ô°Ý:
/Á¦Ç°¼ö·®:
2 /Á¦Çü:
¸Å
Æû¸ñ±âÁØÄÚµå:
199600561 /´ëÇ¥ÄÚµå:
8806454018309 /Ç¥ÁØÄÚµå:
8806454018323
±¸¹ÙÄÚµå:
- /ºñ°í:-
ÄÉÆæÅØÇöó½ºÅ¸(ÄÉÅäÇÁ·ÎÆæ)(¼öÃâ¸í:KEFEN) /
A04203691
Á¦Ç°±Ô°Ý:
/Á¦Ç°¼ö·®:
3 /Á¦Çü:
¸Å
Æû¸ñ±âÁØÄÚµå:
199600561 /´ëÇ¥ÄÚµå:
8806454018309 /Ç¥ÁØÄÚµå:
8806454018330
±¸¹ÙÄÚµå:
- /ºñ°í:-
ÄÉÆæÅØÇöó½ºÅ¸(ÄÉÅäÇÁ·ÎÆæ)(¼öÃâ¸í:KEFEN) /
A04203691
Á¦Ç°±Ô°Ý:
/Á¦Ç°¼ö·®:
6 /Á¦Çü:
¸Å
Æû¸ñ±âÁØÄÚµå:
199600561 /´ëÇ¥ÄÚµå:
8806454018309 /Ç¥ÁØÄÚµå:
8806454018347
±¸¹ÙÄÚµå:
- /ºñ°í:-
ÄÉÆæÅØÇöó½ºÅ¸(ÄÉÅäÇÁ·ÎÆæ)(¼öÃâ¸í:KEFEN) /
A04203691
Á¦Ç°±Ô°Ý:
/Á¦Ç°¼ö·®:
7 /Á¦Çü:
¸Å
Æû¸ñ±âÁØÄÚµå:
199600561 /´ëÇ¥ÄÚµå:
8806454018309 /Ç¥ÁØÄÚµå:
8806454018354
±¸¹ÙÄÚµå:
- /ºñ°í:-
ÄÉÆæÅØÇöó½ºÅ¸(ÄÉÅäÇÁ·ÎÆæ)(¼öÃâ¸í:KEFEN) /
A04203691
Á¦Ç°±Ô°Ý:
/Á¦Ç°¼ö·®:
10 /Á¦Çü:
¸Å
Æû¸ñ±âÁØÄÚµå:
199600561 /´ëÇ¥ÄÚµå:
8806454018309 /Ç¥ÁØÄÚµå:
8806454018361
±¸¹ÙÄÚµå:
- /ºñ°í:-
ÄÉÆæÅØÇöó½ºÅ¸(ÄÉÅäÇÁ·ÎÆæ)(¼öÃâ¸í:KEFEN) /
A04203691
Á¦Ç°±Ô°Ý:
/Á¦Ç°¼ö·®:
30 /Á¦Çü:
¸Å
Æû¸ñ±âÁØÄÚµå:
199600561 /´ëÇ¥ÄÚµå:
8806454018309 /Ç¥ÁØÄÚµå:
8806454018378
±¸¹ÙÄÚµå:
- /ºñ°í:-
ÄÉÆæÅØÇöó½ºÅ¸(ÄÉÅäÇÁ·ÎÆæ)(¼öÃâ¸í:KEFEN) /
A04203691
Á¦Ç°±Ô°Ý:
/Á¦Ç°¼ö·®:
40 /Á¦Çü:
¸Å
Æû¸ñ±âÁØÄÚµå:
199600561 /´ëÇ¥ÄÚµå:
8806454018309 /Ç¥ÁØÄÚµå:
8806454018385
±¸¹ÙÄÚµå:
- /ºñ°í:-
ÄÉÆæÅØÇöó½ºÅ¸(ÄÉÅäÇÁ·ÎÆæ)(¼öÃâ¸í:KEFEN) /
A04203691
Á¦Ç°±Ô°Ý:
/Á¦Ç°¼ö·®:
120 /Á¦Çü:
¸Å
Æû¸ñ±âÁØÄÚµå:
199600561 /´ëÇ¥ÄÚµå:
8806454018309 /Ç¥ÁØÄÚµå:
8806454018392
±¸¹ÙÄÚµå:
- /ºñ°í:-
ÄÉÆæÅØÇöó½ºÅ¸(ÄÉÅäÇÁ·ÎÆæ)(¼öÃâ¸í:KEFEN) /
A04203691
Á¦Ç°±Ô°Ý:
/Á¦Ç°¼ö·®:
300 /Á¦Çü:
¸Å
Æû¸ñ±âÁØÄÚµå:
199600561 /´ëÇ¥ÄÚµå:
8806454018309 /Ç¥ÁØÄÚµå:
8806454018415
±¸¹ÙÄÚµå:
- /ºñ°í:-
ÄÉÆæÅØÇöó½ºÅ¸(ÄÉÅäÇÁ·ÎÆæ)(¼öÃâ¸í:KEFEN) /
A04203691
Á¦Ç°±Ô°Ý:
/Á¦Ç°¼ö·®:
600 /Á¦Çü:
¸Å
Æû¸ñ±âÁØÄÚµå:
199600561 /´ëÇ¥ÄÚµå:
8806454018309 /Ç¥ÁØÄÚµå:
8806454018422
±¸¹ÙÄÚµå:
- /ºñ°í:-
ÁÖ¼ººÐÄÚµå ºÐ¼® ¹× Áߺ¹Ã³¹æ °ËÅä
[ÁÖ¼ººÐÄÚµå ºÐ¼® ¹× Áߺ¹Ã³¹æ °ËÅä]
Drugs By Indication
[Àüüº¸±â]
Drugs By Classification
[Àüüº¸±â]
Á¦Ç°Á¤º¸
Ç׸ñ
³»¿ë
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇѱݾ×
645401830[A04203691]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1¸Å(2017.08.01) (Ãֽžడ)
\126 ¿ø/1¸Å(2016.01.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
Á¦Ç°¼º»ó
ÀÌ ¾àÀº ¹«»öÅõ¸íÀÇ Á¡Âø¼º ¹°ÁúÀ» ¸°Æ®Æ÷¿¡ µµÆ÷ÇÏ°í °íü¸é¿¡ ¹Ú¸®Áö¸¦ µ¤Àº °æ°íÁ¦ÀÌ´Ù
[Á¦ÇüÁ¤º¸ È®ÀÎ]
Æ÷À塤À¯Åë´ÜÀ§
30mg/70§²¡¿70§²/¸Å¡¿7EA, 6EA, 40EA, 10EA
º¸°ü¹æ¹ý
Â÷±¤ÇÑ ±â¹Ð¿ë±â, ½Ç¿Âº¸°ü
µ¿ÀÏÁÖ¼ººÐÄÚµå °Ë»ö¼øÀ§
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
º¹¾àÁ¤º¸
Ç׸ñ
³»¿ë
LACTmed ¹Ù·Î°¡±â
[¹Ù·Î°¡±â]
¾à¸®ÀÛ¿ë
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
Ãà¾àº¹¾àÁöµµ
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
º¹¾àÁöµµ
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
ÀӺο¡´ëÇÑÅõ¿©
*
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
 
FDA : Dµî±Þ
(ÀӽŠ3±â Åõ¿©½Ã )
*
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
*
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
º¸°ü»ó ÁÖÀÇ
Á¶Á¦½Ã ÁÖÀÇ
½É»çÁ¤º¸
ÇмúÁ¤º¸
Ç׸ñ
³»¿ë
DUR (ÀǾàǰ»ç¿ëÆò°¡)
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
µ¶¼ºÁ¤º¸
Ketoprofen ¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do
Mechanism of Action
Ketoprofen¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Ketoprofen is a nonsteroidal anti-inflammatory drug with analgesic and antipyretic properties. Its antiinflammatory effects are believed to be due to inhibition of both cylooxygenase-1 (COX-1) and cylooxygenase-2 (COX-2) which leads to the inhibition of prostaglandin synthesis, and leukotriene synthesis, to have antibrady-kinin activity, as well as to have lysosomal membrane-stabilizing action. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation.
Pharmacology
Ketoprofen¿¡ ´ëÇÑ Pharmacology Á¤º¸ Ketoprofen is a nonsteroidal antiinflammatory drug (NSAID) with analgesic and antipyretic properties. Ketoprofen has pharmacologic actions similar to those of other prototypical NSAIDs, that is thought to be associated with the inhibition of prostaglandin synthesis. Ketoprofen is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and to alleviate moderate pain.
Metabolism
Ketoprofen¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Not Available
Protein Binding
Ketoprofen¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 99%
Half-life
Ketoprofen¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 2-2.5 hours
Absorption
Ketoprofen¿¡ ´ëÇÑ Absorption Á¤º¸ Ketoprofen is rapidly and well-absorbed orally, with peak plasma levels occurring within 0.5 to 2 hours.
Biotransformation
Ketoprofen¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not Available
Toxicity
Ketoprofen¿¡ ´ëÇÑ Toxicity Á¤º¸ LD50 =62.4 mg/kg (rat, oral) Adverse effects from overdose include breathing difficulty, coma, convulsions, drowsiness, high blood pressure, kidney failure, low blood pressure, nausea, sluggishness, stomach and intestinal bleeding, stomach pain, vomiting.
Drug Interactions
Ketoprofen¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Alendronate Increased risk of gastric toxicityMethotrexate The NSAID increases the effect and toxicity of methotrexateCyclosporine Monitor for nephrotoxicityAnisindione The NSAID increases the anticoagulant effectAcenocoumarol The NSAID increases the anticoagulant effectDicumarol The NSAID increases the anticoagulant effectWarfarin The NSAID increases the anticoagulant effect
CYP450 Drug Interaction
[CYP450 TableÁ÷Á¢Á¶È¸]
Food Interaction
Ketoprofen¿¡ ´ëÇÑ Food Interaction Á¤º¸ Take with food to reduce irritation, avoid alcohol.
Drug Target
[Drug Target]
Description
Ketoprofen¿¡ ´ëÇÑ Description Á¤º¸ An ibuprofen-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis. [PubChem]
Dosage Form
Ketoprofen¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule OralSuppository RectalTablet, coated OralTablet, extended release Oral
Drug Category
Ketoprofen¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Inflammatory Agents, Non-SteroidalCyclooxygenase Inhibitors
Smiles String Canonical
Ketoprofen¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
Smiles String Isomeric
Ketoprofen¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ C[C@@H](C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
InChI Identifier
Ketoprofen¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)/f/h18H
Chemical IUPAC Name
Ketoprofen¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 2-[3-(benzoyl)phenyl]propanoic acid
»ç¿ëÀÚÄÁÅÙÃ÷
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-10-30
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
¾Ë¸²
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.
°æ°í
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡± ¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â ·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù